← Human Trials & Peer-Reviewed Studies
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.
Plain-language guide to PMID 34055110 (2021): systematic review of BNP (Nesiritide).
Key Facts
- PMID
- 34055110
- Journal
- Ontario health technology assessment series
- Year
- 2021
- Study type
- Systematic Review
- Authors
- n/a
What This Paper Covers, in Plain Language
What It Covers
This systematic review looks at BNP (Nesiritide).
Heart failure is a complex clinical syndrome that usually presents with breathlessness, leg edema, and fatigue.
Clinically measurable natriuretic neurohormones such as B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are elevated in people with heart failure.
Who the Included Studies Covered
PubMed indexes the participants as adults.
How the Review Was Done
The researchers performed a literature search of previously published systematic reviews of the clinical evidence.
The researchers conducted an overview of reviews and included only reviews with a low risk of bias as assessed using the Risk of Bias in Systematic Reviews tool (ROBIS).
Medical and health economic databases were searched from database inception until July 25, 2019.
The researchers also estimated the budget impact of publicly funding BNP and NT-proBNP tests in people with suspected heart failure in Ontario over the next 5 years.To contextualize the potential value of BNP and NT-proBNP testing, the researchers spoke with people with suspected heart failure.
What Was Measured
Clinically measurable natriuretic neurohormones such as B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are elevated in people with heart failure.
Topics PubMed links to this paper include Diagnostic Tests, Routine, Heart Failure, Natriuretic Peptide, Brain, Ontario, Peptide Fragments, Systematic Reviews as Topic and Technology Assessment, Biomedical.
What This Means in Plain Language
This is a systematic review of BNP (Nesiritide).
Results are reported in around 13 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (Ontario health technology assessment series), a journal based in Canada.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.